Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented, “2Q topline of Ph2 COACH trial in ACH could be one of the bigger catalysts for ASND this year. It will likely come in June, based on recruitment info on clinicaltrials.gov. Our analysis of past trials showed that the 26-week topline of the combination (TransCon CNP + TransCon GH) is very likely to look best-in-class on linear growth, and could even deliver 8-9 cm/yr AGV (annualized growth velocity), exceeding investor expectations of 7-8 cm/yr AGV. Incremental credit assigned to Skytrofa and CNP could send shares +10% in the bull case.”

For an analyst ratings summary and ratings history on Ascendis Pharma click here. For more ratings news on Ascendis Pharma click here.

Shares of Ascendis Pharma closed at $151.25 yesterday.

You May Also Be Interested In

• Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
• Goldman Sachs reviews US consumer staples sales data for August from NielsenIQ
• SEALSQ partners with Palm Technologies for India quantum security